The Connected Clinician: Top Stories of the Week for November 3

NOVEMBER 03, 2017
Kevin Kunzmann
HIV/AIDS, HCV, Zika, Canagliflozin, Ebola, PregnancyInfectious disease has a propensity of making headlines. From the Zika virus epidemic and Ebola outbreaks, to ongoing pursuits to eradicate HIV/AIDs and Hepatitis C, public health’s battle against infection is an always-important discussion.

Even in a week marked by on-scene reporting at MS Paris 2017 and the Annual CHEST Meeting, infectious disease coverage filled MD Magazine. Take a look back, with the Connected Clinician Top Stories of the Week:

HIV Discovered Hiding in Overlooked Memory T Cells

While about 5% of HIV is genetically intact, the small percentage prevents the immune system from fully destroying HIV. 

New Screening Guidelines for Pregnant Women at HCV Risk

As many as 8% of pregnant women worldwide are infected with HCV.

HCV Spikes In Pregnant Wisconsin Women

A new study of HCV infection rates among pregnant women in Wisconsin comes at a time of increased concern about opioid abuse.

AbbVie Announces Positive Elagolix Phase 3 Data

In 2 extension studies, no new safety concerns were identified for the 12-month treatment period.

Alkermes Announces Schizophrenia Therapy Studies

ARISTADA is being investigated as a possible extended-release injectable suspension, as well as INVEGA SUSTENNA in patients with acute exacerbation of schizophrenia.

HIV Vaccine Needed to End Pandemic

 NIAID emphasizes importance of an effective HIV vaccine to achieve a durable end to the HIV/AIDS pandemic.

NIAID Assures Standards Maintained in Rush to Develop Ebola Vaccine

A newly published phase 2 trial described a unique collaborative effort to test 2 candidate vaccines in Liberia against the 2013 Ebola outbreak.

Dr. Aaron Brault, PhD: Sexual Transmission of Zika Through Animal Models

An arbovirologist discusses what animal models tell us about the sexual transmission of Zika virus.

Are Health Care Providers Doing Enough for Patients with Obesity?

The ACTION study revealed that there are several barriers to achieving a healthier lifestyle being faced by patients with obesity.

Canagliflozin Returns Renal Strengths in CANVAS Trial

Janssen's T2D drug for CV risks is undergoing a kidney disease-based phase 3 trial now.

Related Coverage >>>
Copyright© MD Magazine 2006-2018 Intellisphere, LLC. All Rights Reserved.